Literature DB >> 7507238

Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate.

S Yenice1, A T Davis, S A Goueli, A Akdas, C Limas, K Ahmed.   

Abstract

In previous work, we had observed that chromatin-associated nonhistone protein phosphorylation, catalyzed by intrinsic protein kinase reaction in chromatin preparations from human benign prostatic hyperplasia (BPH) prostate samples was markedly elevated, compared with the normal prostate chromatin samples [Rayan et al: Cancer Res 45:2277-2282, 1985]. The properties of this protein kinase reaction were suggestive of the involvement of casein kinase(s). By employing the specific synthetic substrate for casein kinase 2 (CK-2) for assays in cellular fractions, we have shown that this protein kinase is present in human prostate chromatin. Its activity is increased in BPH chromatin by about 25-fold, as compared with its activity in the normal prostate chromatin. This suggests that CK-2 is a possible mediator of the enhanced phosphorylation of chromosomal proteins in BPH chromatin. By comparison, CK-2 activity in chromatin preparations from prostatic carcinoma samples was markedly less elevated than that of the BPH chromatin. Immunohistochemical analysis of the enzyme in human frozen sections of prostate tissue samples showed that the enzyme immunostaining was diffuse in the cytoplasm, but more intense in the nucleus, especially in the nucleoli. In general, the staining corresponded with the enzymic data. However, sections from prostatic carcinoma samples appeared to show differential staining, depending on the Gleason's grade of the sample. The samples with higher Gleason's grade showed less intense immunostain in the nucleus, compared with samples of lower Gleason's grade. Further, regions of sections in samples with higher Gleason's grade did not show any immunostaining. These differences in the characteristics of CK-2 expression in prostatic carcinoma samples may be potentially significant, but need to be evaluated further for their significance to the pathobiology of prostatic neoplasia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507238     DOI: 10.1002/pros.2990240105

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  40 in total

1.  Protein kinase CK2alpha may induce gene expression but unlikely acts directly as a DNA-binding transcription-activating factor.

Authors:  K Ackermann; W Pyerin
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

2.  Assembly of protein kinase CK2: investigation of complex formation between catalytic and regulatory subunits using a zinc-finger-deficient mutant of CK2beta.

Authors:  D A Canton; C Zhang; D W Litchfield
Journal:  Biochem J       Date:  2001-08-15       Impact factor: 3.857

Review 3.  Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.

Authors:  David W Litchfield
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

4.  Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.

Authors:  Fatima Qaiser; Janeen H Trembley; Sarah Sadiq; Iqbal Muhammad; Rubina Younis; Shoaib Naiyar Hashmi; Badar Murtaza; Thomas S Rector; Abdul Khaliq Naveed; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2016-07-19       Impact factor: 3.396

5.  The pleckstrin homology domain-containing protein CKIP-1 is involved in regulation of cell morphology and the actin cytoskeleton and interaction with actin capping protein.

Authors:  David A Canton; Mary Ellen K Olsten; Kyoungtae Kim; Amanda Doherty-Kirby; Gilles Lajoie; John A Cooper; David W Litchfield
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

6.  CK2 interacting proteins: emerging paradigms for CK2 regulation?

Authors:  Mary Ellen K Olsten; Jane E Weber; David W Litchfield
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

7.  Inhibition of human papillomavirus type 16 E7 phosphorylation by the S100 MRP-8/14 protein complex.

Authors:  Sharof Tugizov; Jennifer Berline; Rossana Herrera; Maria Elena Penaranda; Mayumi Nakagawa; Joel Palefsky
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.

Authors:  Andreas Gratz; Uwe Kuckländer; Ricardo Bollig; Claudia Götz; Joachim Jose
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

9.  NKX3.1 is regulated by protein kinase CK2 in prostate tumor cells.

Authors:  Xiang Li; Bin Guan; Sam Maghami; Charles J Bieberich
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

10.  Structural and functional insights into the regulation mechanism of CK2 by IP6 and the intrinsically disordered protein Nopp140.

Authors:  Won-Kyu Lee; Sang Hyeon Son; Bong-Suk Jin; Jung-Hyun Na; Soo-Youl Kim; Kook-Han Kim; Eunice Eunkyeong Kim; Yeon Gyu Yu; Hyung Ho Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.